Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies

被引:1
作者
Piotr Eder [1 ]
Kamila Stawczyk-Eder [1 ]
Katarzyna Korybalska [2 ]
Natasza Czepulis [2 ]
Joanna Luczak [2 ]
Liliana Lykowska-Szuber [1 ]
Iwona Krela-Kazmierczak [1 ]
Krzysztof Linke [1 ]
Janusz Witowski [2 ]
机构
[1] Department of Gastroenterology, Human Nutrition and Internal Diseases, Poznan University of Medical Sciences
[2] Department of Pathophysiology, Poznan University of Medical Sciences
关键词
Adalimumab; Crohn’s disease; Infliximab; Mucosal healing; Trefoil factors;
D O I
暂无
中图分类号
R574.62 [结肠疾病];
学科分类号
1002 ; 100201 ;
摘要
AIM To evaluate whether repeated serum measurements of trefoil factor-3(TFF-3)can reliably reflect mucosal healing(MH)in Crohn’s disease(CD)patients treated with anti-tumor necrosis factor-α(anti-TNF-α)antibodies.METHODS Serum TFF-3 was measured before and after antiTNF-αinduction therapy in 30 CD patients.The results were related to clinical,biochemical and endoscopic parameters.MH was defined as a≥50%decrease in Simple Endoscopic Score for Crohn’s disease(SES-CD).RESULTS SES-CD correlated significantly with CD clinical activity and several standard biochemical parameters(albumin,leukocyte and platelet counts,C-reactive protein,erythrocyte sedimentation rate,fibrinogen).In contrast,SES-CD did not correlate with TFF-3(P=0.54).Moreover,TFF-3 levels did not change significantly after therapy irrespectively of whether the patients achieved MH or not.Likewise,TFF-3 did not correlate with changes in fecal calprotectin,which has been proposed as another biochemical marker of mucosal damage in CD.CONCLUSION Serum TFF-3 is not a convenient and reliable surrogate marker of MH during therapy with TNF-αantagonists in CD.
引用
收藏
页码:135 / 140
页数:6
相关论文
共 7 条
[1]  
Disease monitoring in inflammatory bowel disease[J]. Shannon Chang,Lisa Malter,David Hudesman. World Journal of Gastroenterology. 2015(40)
[2]  
Trefoil factors in inflammatory bowel disease[J]. Luise Aamann,Else Marie Vestergaard,Henning Grφnbk. World Journal of Gastroenterology. 2014(12)
[3]   Mucosal healing and deep remission: What does it mean? [J].
Gerhard Rogler ;
Stephan Vavricka ;
Alain Schoepfer ;
Peter L Lakatos .
World Journal of Gastroenterology, 2013, 19 (43) :7552-7560
[4]   Impact of disease location on fecal calprotectin levels in Crohn's disease [J].
Gecse, Krisztina B. ;
Brandse, Johannan F. ;
van Wilpe, Sandra ;
Lowenberg, Mark ;
Ponsioen, Cyriel ;
van den Brink, Gijs ;
D'Haens, Geert .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2015, 50 (07) :841-847
[5]  
Converging Goals of Treatment for Inflammatory Bowel Disease, from Clinical Trials and Practice[J] . Barrett G. Levesque,William J. Sandborn,Joannie Ruel,Brian G. Feagan,Bruce E. Sands,Jean-Frederic Colombel. Gastroenterology . 2014
[6]  
Treatment algorithms in Crohn's – Up, down or something else?[J] . Ophélie Antunes,Jér?me Filippi,Xavier Hébuterne,Laurent Peyrin-Biroulet. Best Practice & Research Clinical Gastroenterology . 2014 (3)
[7]  
Serum trefoil factors in patients with inflammatory bowel disease .2 Grnbaek Henning,Vestergaard Else Marie,Hey Henrik,Nielsen Jens Nederby,Nex Ebba. Digestion . 2006